Literature DB >> 11315099

Expression of bone sialoprotein and osteopontin in breast cancer bone metastases.

T Ibrahim1, I Leong, O Sanchez-Sweatman, R Khokha, J Sodek, H C Tenenbaum, B Ganss, S Cheifetz.   

Abstract

Bone sialoprotein (BSP) and osteopontin (OPN) are prominent, mineral-associated proteins in the extracellular matrix of bone that have been implicated in the metastatic activity of cancer cells. The expression of BSP, which is normally restricted to mineralizing tissues, has been observed in cancers with a high propensity for forming bone metastases. To investigate the relationship between BSP expression and the formation of bone metastases we have conducted an initial study of the expression of BSP in 10 intraductal breast carcinoma bone metastases using immunostaining and in situ hybridization, and compared the expression with OPN. The metastases were characterized by the infiltration of tumour cells into bone with extensive bone resorption evident. Moderate to strong staining for BSP was observed in all (100%) carcinomas, which also expressed BSP mRNA as determined by in situ hybridization. Variable staining for BSP was also observed in the mineralized bone and expression of BSP mRNA could be observed in osteoblastic cells on the bone surface and in some osteocytes at sites of bone remodelling. Contrary to a previous report, BSP expression could be demonstrated by PCR in three breast cancer cell lines, MCF-7, T47-D and MDA-MB-231. Moreover, in sub-cutaneous tumours formed by MDA-MB-231 breast cancer cells injected into athymic mice, higher immunostaining for BSP was seen in large ulcerating tumours in which mineral deposits were formed. In contrast to BSP, staining for OPN in bone metastases was generally restricted to the interface between tumor cells and bone surface of the carcinomas. While OPN staining was also observed in the cytoplasm of osteoclasts, which showed strong hybridization to a digoxygenin-labelled OPN cRNA probe, expression of OPN was not clearly detectable in the tumour cells. These studies provide the first demonstration of BSP expression by tumour cells in bone metastases and support the concept that BSP may have a role in targeting metastatic cells to bone. Expression of OPN in bone metastases appears to be related to increased bone resorptive activity by osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11315099     DOI: 10.1023/a:1006754605901

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  45 in total

1.  Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins.

Authors:  G K Hunter; P V Hauschka; A R Poole; L C Rosenberg; H A Goldberg
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

2.  Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.

Authors:  H Shiraga; W Min; W J VanDusen; M D Clayman; D Miner; C H Terrell; J R Sherbotie; J W Foreman; C Przysiecki; E G Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

3.  Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers.

Authors:  D Waltregny; A Bellahcène; X de Leval; B Florkin; U Weidle; V Castronovo
Journal:  J Bone Miner Res       Date:  2000-05       Impact factor: 6.741

4.  Human bone sialoprotein. Deduced protein sequence and chromosomal localization.

Authors:  L W Fisher; O W McBride; J D Termine; M F Young
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

5.  Evidence that breast cancer associated microcalcifications are mineralized malignant cells.

Authors:  V Castronovo; A Bellahcene
Journal:  Int J Oncol       Date:  1998-02       Impact factor: 5.650

6.  Bone sialoprotein in serum of patients with malignant bone diseases.

Authors:  W Withold; F P Armbruster; M Karmatschek; H Reinauer
Journal:  Clin Chem       Date:  1997-01       Impact factor: 8.327

7.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

Review 8.  Osteolytic bone metastasis in breast cancer.

Authors:  T Yoneda; A Sasaki; G R Mundy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 9.  Osteopontin: a protein with diverse functions.

Authors:  D T Denhardt; X Guo
Journal:  FASEB J       Date:  1993-12       Impact factor: 5.191

10.  Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer.

Authors:  D Waltregny; A Bellahcène; I Van Riet; L W Fisher; M Young; P Fernandez; W Dewé; J de Leval; V Castronovo
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

View more
  24 in total

1.  Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.

Authors:  Tajneen Natasha; Misty Kuhn; Owen Kelly; Susan R Rittling
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

2.  Secretory pathway Ca2+ -ATPases promote in vitro microcalcifications in breast cancer cells.

Authors:  Donna Dang; Hari Prasad; Rajini Rao
Journal:  Mol Carcinog       Date:  2017-07-28       Impact factor: 4.784

Review 3.  The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs.

Authors:  Robert R Langley; Isaiah J Fidler
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

4.  Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma.

Authors:  Gang Wu; Jing-Jing Guo; Zhen-Yu Ma; Jie Wang; Zhong-Wen Zhou; Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.

Authors:  Said M Elshafae; Wessel P Dirksen; Aylin Alasonyalilar-Demirer; Justin Breitbach; Shiyu Yuan; Noriko Kantake; Wachiraphan Supsavhad; Bardes B Hassan; Zayed Attia; Lucas B Alstadt; Thomas J Rosol
Journal:  Prostate       Date:  2020-04-29       Impact factor: 4.104

Review 6.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

Review 7.  Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers.

Authors:  Thomas E Kruger; Andrew H Miller; Andrew K Godwin; Jinxi Wang
Journal:  Crit Rev Oncol Hematol       Date:  2013-09-07       Impact factor: 6.312

8.  Probing Cell Adhesion Profiles with a Microscale Adhesive Choice Assay.

Authors:  Harsha Kittur; Andy Tay; Avery Hua; Min Yu; Dino Di Carlo
Journal:  Biophys J       Date:  2017-10-17       Impact factor: 4.033

9.  miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells.

Authors:  Mohammad Q Hassan; Yukiko Maeda; Hanna Taipaleenmaki; Weibing Zhang; Mohammad Jafferji; Jonathan A R Gordon; Zhaoyong Li; Carlo M Croce; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

10.  Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics.

Authors:  Alka Jain; Larry W Fisher; Neal S Fedarko
Journal:  Biochemistry       Date:  2008-05-08       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.